BlackRock Inc. disclosed a new investment in Arcturus Therapeutics Holdings Inc. via a recent SEC 13F filing. The asset management firm purchased more than 2.6 million shares.
The investment is valued at approximately $17.57 million. This transaction secures BlackRock a 9.2% ownership stake in the company.
Arcturus Therapeutics develops mRNA-based medicines and vaccines for various diseases. Institutional investors currently hold a significant portion of the firm's total equity.